Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-09-20 |
Bluebird bio (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-09-20 |
Glythera (UK) Iontas (UK) |
antibody drug conjugates (ADC) for difficult-to-treat cancers |
difficult-to-treat cancers. |
development - collaboration |
Cancer - Oncology |
Development agreement |
2017-09-20 |
XBiotech (USA - TX) Cedars-Sinai Medical Center (USA - CA) |
MABp1 (bermekimab) |
patients with advanced pancreatic adenocarcinoma and cachexia |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-09-18 |
Immunocore (UK) Bill and Melinda Gates Foundation (USA) |
ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics |
HIV infection, tuberculosis |
development |
Infectious diseases |
Development agreement |
2017-09-18 |
Brammer Bio (USA - MA) |
expansion of Alachua site |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-09-17 |
Merck&Co (USA - NJ) Zymeworks (Canada) |
bispecific antibody therapeutic candidates generated through use of the Azymetric™ platform |
|
development - licensing - commercialisation |
undisclosed |
Milestone |
2017-09-14 |
Daiichi Sankyo (Japan) The University of Texas MD Anderson Cancer Center (USA - TX) |
quizartinib, DS-3032, DS-3201, and PLX51107 |
acute myeloid leukemia (AML) |
development |
Cancer - Oncology |
Development agreement |
2017-09-13 |
Onxeo (France) Monopar Therapeutics (USA - IL) |
Validive® (clonidine mucoadhesive buccal tablet) |
severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer |
licensing |
Cancer - Oncology |
Licensing agreement |
2017-09-13 |
Eyevensys (France) |
pre-clinical director |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
2017-09-12 |
Alexion Pharmaceuticals (USA - CT) |
|
|
restructuring |
Rare diseases - Genetic diseases |
Restructuring |
2017-09-12 |
TiGenix (Belgium) |
head of medical department (US), director |
|
nomination |
Autoimmune diseases – Inflammatory diseases - Cardiovascular diseases |
Nomination |
2017-09-12 |
Basilea Pharmaceutica (Switzerland) Cardiome Pharma (Canada) |
Zevtera®/Mabelio® (ceftobiprole) |
severe community-acquired and hospital-acquired pneumonia |
distribution - commercialisation |
Infectious diseases |
Distribution agreement |
2017-09-12 |
ProQR Therapeutics (The Netherlands) Amylon Therapeutics (The Netherlands) |
therapeutics for beta amyloid related disorders |
beta amyloid related disorders |
establishment of a new subsidiary in the EU |
CNS diseases - Neurological diseases - Neurodegenerative diseases |
Establishment of a new subsidiary in the EU |
2017-09-12 |
Lysogene (France) |
clinical advisory board |
|
nominatin |
Rare diseases - Genetic diseases |
Nomination |
2017-09-11 |
Teva Pharmaceutical (Israel) |
president and chief executive officer |
|
nomination |
|
Nomination |
2017-09-11 |
Allergy Therapeutics (UK) |
clinical director, head of clinical science, senior pharmaceutical physician |
|
nomination |
Allergic diseases |
Nomination |
2017-09-11 |
Synpromics (UK) |
new facility at the Roslin Innovation Centre |
|
opening of new premises |
Technology - Services |
Opening of new premises |
2017-09-11 |
Amphivena Therapeutics (USA - CA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-09-11 |
Iovance Biotherapeutics (USA - CA) TrakCel (USA - NJ) |
scheduling and logistics tool that automates the supply chain for adoptive cell therapy products that utilize tumor-infiltrating lymphocyte (TIL) technology. |
|
collaboration |
Cancer - Oncology - Technology - Services |
Collaboration agreement |
2017-09-07 |
Adaptimmune (UK) GSK (UK) |
NY-ESO SPEAR T-cell therapy program including GSK3377794 |
synovial sarcoma, myxoid round cell liposarcoma |
licensing |
Cancer - Oncology |
Exercise of an option agreement |